Description
Now in its fifth year, ACI s Paragraph IV Disputes conference has become the most trusted source for the ins and outs of Paragraph IV litigation. This first and original conference of its kind serves as the litigation playbook for brand name and generic drug companies in the high-stakes arena of Hatch-Waxman litigation. The inherent intensity of Paragraph IV litigation has been magnified of late by the seemingly unending repercussions of the Hatch-Waxman reforms of the MMA, pending Patent Reform legislation, the approval of an abbreviated pathway for follow-on biological products and the threat of proposed legislation, which may make settlements of these matters near impossible let alone illegal. These factors have all added to the complexity of this litigation, and have also raised the monetary ante to unprecedented heights. In this environment, it is imperative that brand name and generic pharmaceutical companies and their counsel, have the offensive moves and defensive plays that they need to meet the challenges of pharmaceutical patent endgame litigation.
ACI s Paragraph IV Disputes conference has been designed to give counsel for both brand name and generic drug companies the critical up-to-the minute information that they need to plan their Hatch-Waxman litigation strategies. An experienced faculty comprised of respected and renowned counsel for both brand name and generic pharmaceutical companies will provide insights on every facet of Paragraph IV litigation from pre-litigation concerns to the commencement of suit through to final adjudication and every step in between.
